RxDoctor Payments Data

Jessi Thompson, APRN

Family · Wilmington, DENPI 1295139624

Payments from drug & device makers

$824in general payments, 2019–2025

Across 43 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$178
  • AbbVie$119
  • AstraZeneca$108
  • Exact Sciences$76
  • Astellas Pharma US Inc$63
  • Dexcom, Inc.$62
  • plus $217 from 7 others

What the payments were for

  • Food & beverage$824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$824 in reported general payments places this provider in the 55th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$28,813
Medicare patients
146
Services billed
470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide21$26,303
Atorvastatin Calcium57$853
Levothyroxine Sodium44$513
Gabapentin18$416
Metformin Hcl29$219
Amlodipine Besylate21$212
Omeprazole17$176
Hydrochlorothiazide22$166
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$158
Losartan Potassium14$144
Rosuvastatin Calcium21$141
Trazodone Hcl13$119
Fluticasone Propionate12$104
Lisinopril17$99
Alprazolam16$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$54$26,30321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 523 family providers in Delaware.

Other family in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →